BII was established in July 2001 to train manpower and build capabilities in bioinformatics. BII's research focus centres around knowledge discovery from biological data, exploiting high-end computing in biomedicine, advancing molecular imaging of biological processes, modelling of drug design and delivery, computational proteomics and systems biology.

The mission of the Bioprocessing Technology Institute (BTI) is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocess community. Spearheading bioprocess R&D, the BTI has core expertise in expression engineering, animal cell technology, stem cells, microbial fermentation, product characterisation, downstream processing, purification and stability, with supporting proteomics and microarray platform technologies. BTI, with its R&D and its cGMP manufacturing capabilities, bridges the gaps between discovery, process development and commercialisation.

Established in June 2000 as the Singapore Genomics Program, the renamed Genome Institute of Singapore (GIS) is a national flagship initiative with a global vision that seeks to use genomic sciences to improve public health and prosperity.
As a centre for genomic discovery, GIS pursues the integration of technology, genetics, and biology towards the goal of individualised medicine. The scientific focus will be to investigate post-sequence genomics; to understand the genetic architecture of pan-Asian populations with emphasis on cancer biology, pharmacogenomics, stem cell biology and infectious diseases. The genomics infrastructure at GIS will be utilized to train new scientific talent, to function as a bridge for academic and industrial research and explore scientific questions of high impact.
Dr Edison Liu, former Director of the National Cancer Institute's Division of Clinical Sciences in the U.S.A., heads the GIS as the Executive Director.

Since 2003, the Institute of Bioengineering and Nanotechnology has carved out a unique niche at the interface of bioengineering and nanotechnology with its impactful research. Led by Executive Director Professor Jackie Y. Ying, the Institute’s multidisciplinary research teams have contributed to advancements in science, engineering and medicine by generating new knowledge and creating innovative materials, devices, processes and tools to transform healthcare and medical technologies.

• Drug and Gene Delivery - where the controlled release of therapeutics involves the use of functionalized polymers, hydrogels and biologics for targeting diseased cells and organs, and for responding to specific biological stimuli.

• Cell and Tissue Engineering - where biomimicking materials, stem cell technology, microfluidic systems, and bioimaging tools are combined to develop novel approaches to regenerative medicine and artificial organs.

• Biosensors and Biodevices - which involve nanotechnology and microfabricated platforms for high-throughput biomarkers screening, automated biologics synthesis, and rapid disease diagnosis.

• Pharmaceuticals Synthesis and Nanobiotechnology - which encompass the efficient catalytic synthesis of chiral pharmaceuticals, and new nanocomposite materials for sustainable technology and alternative energy generation.

The Institute of Medical Biology (IMB) has a strategic, programme-directed portfolio of research focused on issues at the critical interface between basic science and medicine. The aim is to facilitate the development of translational research by building bridges between clinical and basic science. IMB is currently hosting research programmes concerned with different aspects of human disease.

The current programmes within IMB are the Singapore Onco-Genome project, Regenerative Medicine, Papillomavirology, Epithelial Biology and the Lab of Stem Cell Biology from Singapore Stem Cell Consortium (SSCC). The Institute of Medical Biology will help scientists and clinicians to work closely together to support, inform and refine each other’s strengths and specializations to increase the efficiency of the translation process, and ultimately contribute towards a better quality of life for all.

The Institute of Molecular and Cell Biology (IMCB) was established in 1987 to help develop and support biomedical R&D capabilities in Singapore. Currently the institute has 34 independent research groups with more than 400 staff members.

Today, IMCB has established itself as a world-class research institute in biomedical sciences with core strengths in cell cycling, cell signaling, cell death, cell motility and protein trafficking. Its recent achievements include being part of an international consortium which successfully sequenced the entire pufferfish (Fugu) genome - a world first. IMCB was awarded the Nikkei Prize 2000 for Technological Innovation in recognition of its growth into a leading international research centre and its collaboration with industry and research institutes world-wide.

The Singapore Institute for Clinical Sciences (SICS) will accelerate the translation of basic discoveries into new diagnostics and therapeutics.  SICS will be distinguished by its focus on clinical science and the use of innovative approaches and technologies that enable the efficient and effective study of human health and disease. In so doing, the institute will attract, train and nurture a new type of clinician scientist.  SICS will collaborate with universities, research institutes and clinical programs to achieve the ultimate goal of improving human health as well as Singapore’s economic well-being.

The research focus of SICS will be centered on the human as the model system, and will complement other A*STAR Research Institutes by focusing on the clinical and translational research portion of the spectrum of biomedical research.  SICS will have both intramural research programs and extramural outreach initiatives.
 
Intramural Programs are focused on specific disease areas.  The initial programs at SICS are Genetic Medicine, Hepatic Infectious Diseases andMetabolic Diseases. SICS participates in, or provides oversight to programs external to our institute through our Extramural Programs: Lilly-NUS/SICS Joint Fellowship, Metabolic Interest Group, Supporting the National Medical Research Council in coordinating the STaR Investigatorship Awards and Translational and Clinical Research Flagship Awards